Essentials for physicians and health care professionals ordering and interpreting urinary screens for drugs of abuse.
- Dr. Edward Randell
Essentials for physicians and health care professionals ordering and - - PowerPoint PPT Presentation
Essentials for physicians and health care professionals ordering and interpreting urinary screens for drugs of abuse. Dr. Edward Randell Disclosure of Potential for Conflict of Interest FINANCIAL DISCLOSURE Grants/Research Support: CIHR and
Amphetamines and Methamphetamine Opiates Benzodiazepines Cocaine Barbiturates Methadone Phencyclidine Marijuana Oxycodone
Check out discuss of similar case at: http://paindr.com/two-puffs-too-bad-demystifying- marijuana-urine-testing/
A 40 years old female receiving Oxycodone, presents to a pain clinic for routine follow-up visit. A random urine drug screen is done by immunoassay and she tests positive for Marijuana (cannabinoids positive). When asked, she admits “I only smoked two puffs five days ago”. Fact or Myth?
Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86.
Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86.
Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86.
Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012). They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of general internal medicine, 27(11), 1521-1527.
Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012). They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of general internal medicine, 27(11), 1521-1527.
There was no significant differences in interpreting drug screens among medical residents stating confidence in their ability versus those acknowledging lack of confidence.
1950’s Emergency Rooms and Death investigations 1970’s: Addiction treatment & criminal justice 1970’s Methadone maintenance/Opioid Treatment/Military Workplace/Industry/Govt. Highway safety
Method Common Abbreviation Cloned enzyme donor immunoassay CDIA Enzyme-linked immunosorbent assay ELISA Enzyme-multiplied immunoassay technique EMIT Fluorescence polarization immunoassay FPIA Radioimmunoassay RIA Point of care testing methods POCT Gas Chromatography Mass Spectrometry GC-MS Liquid Chromatography Ultraviolet Detection HPLC-UV Liquid Chromatography High Resolution Mass spectrometry LC-hrMS Liquid Chromatography tandem mass spectrometry LC-MS/MS Liquid Chromatography time-of-flight mass spectrometry LC-TOF Thin Layer Chromatography TLC
Barbosa, S. S., Leal, F. D., Padilha, M. C., Silva, R. S., Pereira, H. M. G., Aquino Neto, F. R., & Silva Júnior, A. I. D. (2012). Specificity and selectivity improvement in doping analysis using comprehensive two-dimensional gas chromatography coupled with time-of-flight mass spectrometry. Química Nova, 35(5), 982-987.
20
Eichhorst, J. C., Etter, M. L., Rousseaux, N., & Lehotay, D. C. (2009). Drugs of abuse testing by tandem mass spectrometry: a rapid, simple method to replace immunoassays. Clinical biochemistry, 42(15), 1531-1542.
Screening Screening/Confirmatory Analysis Immunoassay GC-MS or LC-MS/MS Ability to detect drug class (Sensitivity) Low to nil for synthetic opioids but fair for others High Ability to discriminate drug from similar compounds (Specificity) Variable-false positives and false negatives High Use Qualitative screen Quantitative confirmation Cost Variable Variable TAT rapid Many days Application Works best for screening drug- free population; may be less useful in pain-management. Definitive & Legally defensible Interpretation Complex Complex
Patient reports taking the drug
True Positive
reported.
reported False Negative
taking the drug.
be detected.
False Positive
administration of a cross- reacting substance True Negative
reported.
Duration of use
Administration Route Urine volume Hydration Status
Diet
Urine pH
Concurrent Medications
Urinary frequency
Dosage Intervals
Disease State Body Weight
Individual metabolism
Target Drugs Interfering Drugs Amphetamines Diet Pills, Vicks inhaler (US), Trazodone, Aripiprazole, Promethazine and Phentermine Marijuana Efavirenz (Antiretroviral), baby shampoo and soap, pantoprazole and possibly other proton pump inhibitors Hydromorphone Hydrocodone Methadone Quetiapine Fentanyl Trazodone TCAs Quetiapine Opiates/Morphine Poppy Seeds, Quinolone antibiotics Benzodiazepines Sertraline PCP Venlafaxine
Agents that can cause positive results on amphetamine immunoassay.
Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008, January). Urine drug screening: practical guide for clinicians. In Mayo Clinic Proceedings (Vol. 83, No. 1,
Cross-reactivity is a common problem for UDS relying on immunoassay technique.
Moeller K E et al. Mayo Clin Proc. 2008;83:66-76
Drug/Class Immunoassay Screen Mass Spectrometry Benzodiazepines Oxazepam Specific Drugs: Diazepam, Oxazepam, Loraxepam, Temazepam, Alprazolam, Clonazepam… Opiates Morphine Specific Drugs: Morphine, Codeine, Oxycodone, Fentanyl, Hydromorphone…. Cocaine Cocaine Metabolite Cocaine and Benzoeconine Marijuana THC metabolite THC and THC-COOH Amphetamine & Methamphetamine Amphetamine & Methamphetamine Specific Drugs: Amphetamine, MDA, MDMA, metamphetamine…
Some Mass Spectrometry methods are non-targeted – meaning that they detect “everything” and both suspected and unsuspected can be explored.
Moeller K E et al. Mayo Clin Proc. 2008;83:66-76
For both Morphine and Codeine
Cutoffs determine the drug concentration at which a positive result is reported. This is not the same as a detection limit.
2000 4000 6000 8000 10000 12000
10 20 30 40 50 60
Cocaine (base) 42 mg smoked
Benzoyleconine Ecgonine Methyl ester Cocaine
Cone, E. J., Sampson-Cone, A. H., Darwin, W. D., Huestis, M. A., & Oyler, J. M. (2003). Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. Journal of analytical toxicology, 27(7), 386-401
Detected by immunoassay (300 µg/L)
Marijuana (Heavy use) (Moderate use) Benzodiazepines (Long acting)
Barbiturate (long acting)
2 days 4 days 6 days 1 week 2 weeks (Short acting)
(Short)
(Single use) Amphetamine & Metamphetamine Alcohol and Phencyclidine
Moeller K E et al. Mayo Clin Proc. 2008;83:66-76
Cocaine
Meperidine
1 days 2 days 3 days
Methadone
Oxycodone Morphine from Heroine Morphine
Moeller K E et al. Mayo Clin Proc. 2008;83:66-76
Codeine 4 days Up to 6 days if metabolite tested Heroine only a few hours Often missed Often missed
Minutes Hours Days Weeks Months Years Blood Saliva Urine Sweat Hair
Benzodiazepine assays are prone to false negatives.
Smith, M. L., Shimomura, E. T., Summers, J., Paul, B. D., Nichols, D., Shippee, R., ... & Cone, E. J. (2000). Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration. Journal of Analytical Toxicology, 24(7), 522-529.
Drug Mass Spectrometry Heroine 6 monoacetyl morphine Morphine Codeine Codeine Morphine Hydrocodone Oxycodone Oxycodone Oxymorphone Hydrocodone Poppy Seeds Morphine Hydrocodone Hydrocodone Hydromorphone Fentanyl Fentanyl Norfentanyl
Opioid
binding opioid receptors
Hydromorphone,
Meperidine,…
from opium poppy
Many Opioids and Benzodiazepines are missed by routine immunoassay UDS.
(Codeine & Morphine) (Morphine) (6 monoaceylmorphine & Morphine) (Morphine) (Nothing) (Which opioid? Screen may not measure.) (Most screens do not measure hydromorphone. Request confirmatory procedure)
Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA, 315(15), 1624-1645. Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008). Urine drug screening: practical guide for clinicians. In Mayo Clinic Proceedings (Vol. 83, No. 1, pp. 66-76). Elsevier Hammett-Stabler, C.A., Weber, L.R. (2008) A Clinical Guide to Urine Drug Testing. CME monograph available at http://ccoe.rbhs.rutgers.edu/online/ARCHIVE/endurings/09MC07.pdf Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86. Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012). They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of general internal medicine, 27(11), 1521-1527. Pesce, A., West, C., Egan-City, K., & Clarke, W. (2012). Diagnostic accuracy and interpretation of urine drug testing for pain patients: an evidence-based approach. In Toxicity and drug testing.